Lily Wound

Lily Wound, a partner in Goodwin’s Technology and Life Sciences groups, has extensive experience representing pharmaceutical, biotechnology, and other life sciences companies in a wide range of complex commercial, corporate, and licensing transactions, including those involving gene therapy, gene editing, engineered cell therapy, and genomic testing. With broad knowledge of licensing and collaboration matters, Lily has worked on some of the most complex life sciences collaborations in the industry and has handled transactions at every stage of the life cycle of a life sciences product and has represented early stage to big pharma companies in connection with these transactions. In addition, her roster of domestic and international clients extends to the healthcare, healthcare information and technology, cosmetics, publishing, media, internet, software, and technology industries.

Lily is a Co-Chair of Goodwin’s Climate Tech practice, which is focused on providing top tier legal services to entrepreneurs, operating companies, and investors who are pioneers in the sustainability market. 

Lily is also a member of Goodwin’s PropSci practice which is focused on supporting the intersection of Real Estate and Life Sciences through thoughtful collaboration across the two practice areas. As a key contributor to the group and Steering Committee, Lily stays up to date on relevant market trends impacting the PropSci sector to effectively support clients involved in this space.

Lily joined Goodwin in 2019 from WilmerHale, where she served as counsel. She has also served as in-house counsel at Hearst Corporation, where she advised on all aspects of Hearst's businesses relating to healthcare information and technology, traditional media, new media, and digital media. Her responsibilities at Hearst included serving as general counsel for an evidence-based medical information and technology company and leading all complex transactions in the newspapers division.

Lily’s representative matters include advising:

• Envisagenics, an AI-driven biotechnology company focused on RNA splicing diseases, in its research collaboration with BMS to identify alternative splicing-derived targets for therapeutic development in oncology
• Serotiny in its research collaboration with Janssen to use its AI-driven tMDP mining and design platform to optimize CAR designs for cellular therapy
• SIGA Technologies in its international promotion agreement for TPOXX™ with Meridian Medical Technologies and its international procurement orders for TPOXX™ for health security preparedness in response to the monkeypox outbreak
• LEXEO Therapeutics in its acquisition of Stelios Therapeutics and its gene therapy programs for rare cardiovascular diseases
• EQRx in its strategic collaboration and license agreement with Hansoh Pharmaceutical for ex-China rights to its EGFR inhibitor, almonertinib, which is approved in China for EGFR T790M mutation-positive non-small cell lung cancer (NSCLC)
• EQRx in its license agreement with G1 Therapeutics for lerociclib, an oral CDK4/6 inhibitor, in the U.S., Europe, Japan and all other global markets, excluding the Asia-Pacific region (except Japan)
• Landmark Bio in its formation as an industry-academia research and development consortium focused on innovations in gene and cell therapies and immunotherapies, advanced biologic innovation and manufacturing, and accelerating the practical application and commercialization of these therapies. Founding members include Harvard University, Fujifilm, Massachusetts Institute of Technology, Diosynth Biotechnologies, Cytiva (formerly part of GE Healthcare Life Sciences) and Alexandria Real Estate Equities, Inc. Landmark Bio recently closed on its initial $76 million fundraising round
• Editas Medicine in a strategic research collaboration and cross-licensing agreement with BlueRock Therapeutics to discover, develop, and manufacture novel engineered cell medicines*
• Foundation Medicine in its partnership with Natera to develop and commercialize personalized circulating tumor DNA (ctDNA) monitoring assays*
• Voyager Therapeutics in a global strategic collaboration with AbbVie to develop and commercialize vectorized antibodies directed against tau for the treatment of Alzheimer's disease and other neurodegenerative diseases*
• Spark Therapeutics in its licensing and supply agreements with Novartis to develop and commercialize investigational voretigene neparvovec outside the United States*
• Spark Therapeutics in a licensing agreement with Selecta Biosciences for exclusive worldwide rights to Selecta's proprietary Synthetic Vaccine Particles platform technology*

*Denotes experience prior to joining Goodwin.

Lily serves on the Board of Managers of Life Sciences Cares New York, whose mission is to leverage the intellectual, financial, and human capital of the life sciences industry in an effort to reduce the effects of poverty.

Lily serves as an elected Board member of Asian Women for Health, a peer-led, community-based network dedicated to advancing Asian women’s health and wellness through education, advocacy, and support.

Lily serves as a member of the Advisory Board for Women In Bio-MetroNY. In addition, Lily has served for eight years as National Chair and Metro-NY Chair of Young Women In Bio, a national organization focused on promoting STEM, and supporting opportunities in STEM, to girls from elementary school through high school. Young Women in Bio is part of Women in Bio.

SPEAKER AND MODERATOR ENGAGEMENTS

Lily frequently participates in speaking and moderating engagements with Alexandria/LaunchLabs and other incubator and accelerator programs. Recent engagements include:

• Moderator, “Exploring the Economic and Legal Complexities of In Silico Research and Novel Therapeutic Discovery Collaboration Agreements,” JP Morgan KPMG Symposium, JP Morgan Healthcare Conference, January 2023
• Speaker, “The Path from Research to Commercialization: Tech Transfer and Licensing for Innovators,” Activate as part of its “Collisions with Activate” program, July 2022
• Speaker, “The Path from Innovation to Commercialization: Licensing and Partnering,” JETRO (Japan External Trade Organization), July 2022
• Speaker, “Licensing Pharmaceutical Inventions” Program, The Pauline Newman IP American Inn of Court, April 2022
• Speaker, “Licensing Issues in the Life Sciences Industry,” Practicing Law Institute’s Advanced Licensing Agreements, New York, 2022
• Speaker, “Licensing and Partnering,” Startup City Acceleration Program with JETRO and Cambridge Innovation Center, January 2022
• Speaker, “Due Diligence: Investor Expectations,” Alexandria/LaunchLabs, June 2021 
• Speaker, “University Licensing and Equity Trends,” Alexandria/LaunchLabs, March 2021
• Speaker, “Licensing Issues in the Life Sciences Industry,”  Practicing Law Institute’s Advanced Licensing Agreements, San Francisco, New York, and Chicago, 2021 
• Speaker, “Getting Your IP House in Order for Investors,” Alexandria/LaunchLabs, October 2020 
• Speaker, “Demystifying Term Sheets,” Alexandria/LaunchLabs, July 2020
• Speaker, “Confidentiality Agreements – To Disclose or Not to Disclose,” Alexandria/LaunchLabs, May 2020
• Speaker, “Licensing Issues in the Life Sciences Industry,” Practicing Law Institute’s Advanced Licensing Agreements, San Francisco and New York, 2020
• Lead speaker and organizer, “Corporate Partnering,” ELabNYC Bootcamp, 2018 and 2019
• Speaker, “The Many Hats of Women in Bio,” Women in Bio Convention, 2018
• Moderator, “Future of Life Sciences and Tech,” Young Women in Bio event
• Featured Panelist, “The Path to Corporate Partnership,” alumni event by ELabNYC and Alexandria LaunchLabs